Abstract
PURPOSE: To examine the features of available Framingham-based risk calculation tools and review their accuracy and feasibility in clinical practice.
DATA SOURCES: medline, 1966–April 2003, and the google search engine on the Internet.
TOOL AND STUDY SELECTION: We included risk calculation tools that used the Framingham risk equations to generate a global coronary heart disease (CHD) risk. To determine tool accuracy, we reviewed all articles that compared the performance of various Framingham-based risk tools to that of the continuous Framingham risk equations. To determine the feasibility of tool use in clinical practice, we reviewed articles on the availability of the risk factor information required for risk calculation, subjective preference for 1 risk calculator over another, or subjective ease of use.
DATA EXTRACTION: Two reviewers independently reviewed the results of the literature search, all websites, and abstracted all articles for relevant information.
DATA SYNTHESIS: Multiple CHD risk calculation tools are available, including risk charts and computerized calculators for personal digital assistants, personal computers, and web-based use. Most are easy to use and available without cost. They require information on age, smoking status, blood pressure, total and HDL cholesterol, and the presence or absence of diabetes. Compared to the full Framingham equations, accuracy for identifying patients at increased risk was generally quite high. Data on the feasibility of tool use was limited.
CONCLUSIONS: Several easy-to-use tools are available for estimating patients’ CHD risk. Use of such tools could facilitate better decision making about interventions for primary prevention of CHD, but further research about their actual effect on clinical practice and patient outcomes is required.
DISCLOSURE: Drs. Sheridan and Pignone have participated in the development of Heart-to-Heart, one of the risk tools evaluated within. They have also received speaking and consulting fees from Bayer, Inc. Bayer, Inc. has licensed the Heart-to-Heart tool.
Similar content being viewed by others
References
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US preventive services task force. Ann Intern Med. 2002;136:161–72.
Grundy SM, Bazzarre T, Cleeman J, et al. Beyond secondary prevention: identifying the high-risk patient for primary prevention: medical office assessment: Writing Group I. Circulation. 2000;101:E3-E11.
The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413–46.
Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388–91.
Montgomery AA, Fahey T, MacKintosh C, Sharp DJ, Peters TJ. Estimation of cardiovascular risk in hypertensive patients in primary care. Br J Gen Pract. 2000;50:127–8.
Chatellier G, Blinowska A, Menard J, Degoulet P. Do physicians estimate reliably the cardiovascular risk of hypertensive patients? Medinfo. 1995;8(Part 2):876–9.
Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ. 1995;310:975–8.
Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med. 1996;124:414–21.
Meland E, Laerum E, Lehmann EH. Assessment of coronary heart disease risk. II. A clinical multicentre study of general practitioners’ risk assessment. Fam Pract. 1994;11:122–6.
Meland E, Laerum E, Stensvold I. Assessment of coronary heart disease risk. I. A postal inquiry among primary care physicians. Fam Pract. 1994;11:117–21.
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–5.
Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481–92.
Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard RH, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 2001;323:75–81.
Tunstall-Pedoe H. The Dundee coronary risk-disk for management of change in risk factors. BMJ. 1991;303:744–7.
ERICA Research Group. Prediction of coronary heart disease in Europe. The 2nd report of the WHO-ERICA Project. Eur Heart J. 1991;12:291–7.
Menotti A, Lanti M, Puddu PE, Kromhout D. Coronary heart disease incidence in northern and southern European populations: a reanalysis of the seven countries study for a European coronary risk chart. Heart. 2000;84:238–44.
Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–8.
Zodpey SP, Kulkarni HR, Vasudeo ND, Chaubey BS. A risk scoring system for prediction of coronary heart disease based on multivariate analysis: development and validation. Indian Heart J. 1994;46:77–83.
Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.
Menotti A, Puddu PE, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J. 2000;21:365–70.
Shaper AG, Pocock SJ, Phillips AN, Walker M. Identifying men at high risk of heart attacks: strategy for use in general practice. BMJ. Clin Res Ed. 1986;293:474–9.
Game FL, Bartlett WA, Bayly GR, Jones AF. Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. Diabetes Obes Metab. 2001;3:279–86.
Murray CJ, Lauer JA, Hutubessy RC, et al. Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet. 2003;361:717–25.
Liao Y, McGee DL, Cooper RS, Sutkowski MB. How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. Am Heart J. 1999;137:837–45.
Liao Y, McGee DL, Cooper RS. Prediction of coronary heart disease mortality in blacks and whites: pooled data from two national cohorts. Am J Cardiol. 1999;84:31–6.
Grundy SM, D’Agostino RB Sr, Mosca L, et al. Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood Institute workshop. Circulation. 2001;104:491–6.
D’Agostino RB Sr, Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001;286:180–7.
Smith SC Jr, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577–9.
Yeo WW, Yeo KR. Predicting CHD risk in patients with diabetes mellitus. Diabet Med. 2001;18:341–4.
Jones AF, Walker J, Jewkes C, et al. Comparative accuracy of cardiovascular risk prediction methods in primary care patients. Heart. 2001;85:37–43.
Durrington PN, Prais H, Bhatnagar D, et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet. 1999;353:278–81.
McManus RJ, Mant J, Meulendijks CF, et al. Comparison of estimates and calculations of risk of coronary heart disease by doctors and nurses using different calculation tools in general practice: cross sectional study. BMJ. 2002;324:459–64.
Wallis EJ, Ramsay LEUI, Haq I, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. BMJ. 2000;320:671–6.
Wierzbicki AS, Reynolds TM, Gill K, Alg S, Crook MA. A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease. J Cardiovasc Risk. 2000;7:63–71.
Isles CG, Ritchie LD, Murchie P, Norrie J. Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods. BMJ. 2000;320:690–1.
Pignone MP, Phillips CJ, Atkins D, Teutsch SM, Mulrow CD, Lohr KN. Screening and treating adults for lipid disorders. Am J Prev Med. 2001;20:77–89.
Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89–92.
Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA. 2000;284:311–8.
Navas-Nacher EL, Colangelo L, Beam C, Greenland P. Risk factors for coronary heart disease in men 18–39 years of age. Ann Intern Med. 2001;134:433–9.
Miura K, Daviglus ML, Dyer AR, et al. Relationship of blood pressure to 25-year mortality due to coronary heart disease, cardiovascular diseases, and all causes in young adult men: the Chicago Heart Association Detection Project in Industry. Arch Intern Med. 2001;161:1501–8.
Ashley EA, Raxwal V, Froelicher V. An evidence-based review of the resting electrocardiogram as a screening technique for heart disease. Prog Cardiovasc Dis. 2001;44:55–67.
Greenland P, Smith SC Jr, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation. 2001;104:1863–7.
Lowensteyn I, Joseph L, Levinton C, Abrahamowicz M, Steinert Y, Grover S. Can computerized risk profiles help patients improve their coronary risk? The results of the Coronary Health Assessment Study (CHAS). Prev Med. 1998;27:730–7.
Hall LM, Jung RT, Leese GP. Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ. 2003;326:251–2.
Paterson JM, Llewellyn-Thomas HA, Naylor CD. Using disease risk estimates to guide risk factor interventions: field test of a patient workbook for self-assessing coronary risk. Health Expect. 2002;5:3–15.
Kreuter MW, Strecher VJ. Changing inaccurate perceptions of health risk: results from a randomized trial. Health Psychol. 1995;14:56–63.
Strecher VJ, Greenwood T, Wang C, Dumont D. Interactive multimedia and risk communication. J Natl Cancer Inst Monogr. 1999;25:134–9.
Avis NE, Smith KW, McKinlay JB. Accuracy of perceptions of heart attack risk. What influences perceptions and can they be changed? Am J Public Health. 1989;79:1608–12.
Engberg M, Christensen B, Karlsmose B, Lous J, Lauritzen T. General health screenings to improve cardiovascular risk profiles: a randomized controlled trial in general practice with 5-year follow-up. J Fam Pract. 2002;51:546–52.
Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 2000;320:709–10.
Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 1996;348:387–8.
Joint British recommendations on prevention of coronary heart disease in clinical practice: summary. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, British Diabetic Association. BMJ. 2000;320:705–8.
Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart. 1998;80(suppl 2):S1-S29.
Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998;140:199–270.
McCormack JP, Levine M, Rangno RE. Primary prevention of heart disease and stroke: a simplified approach to estimating risk of events and making drug treatment decisions. CMAJ. 1997;157:422–8.
Jones AF, Game FL. Cardiovascular risk assessment. Modern Hypertension Management. 1999;1:10–3.
Office of the Surgeon General. The Health Benefits of Smoking Cessation: A Report of the Surgeon General. 1990. Washington DC: US Department of Health and Human Services, Public Health Service and Centers for Disease Control.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sheridan, S., Pignone, M. & Mulrow, C. Framingham-based tools to calculate the global risk of coronary heart disease. J GEN INTERN MED 18, 1039–1052 (2003). https://doi.org/10.1111/j.1525-1497.2003.30107.x
Issue Date:
DOI: https://doi.org/10.1111/j.1525-1497.2003.30107.x